Search Patents
  • PHARMACEUTICAL, PHYTO-CANNABINOID BASED COMPOSITIONS
    Publication number: 20220202764
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of the cannabinoids tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC) and tetrahydrocannabinol (THC) for use in the prevention or treatment of disorders related to depression, fatigue, deteriorated alertness, excessive daytime sleepiness and reduced appetite, wherein the relative weight ratios of THCV:CBG:CBC:THC are between 1-10:1-10:1-10:1-10, and to a method of treating a mammal in need thereof, said mammal suffering from a disorder related to depression, fatigue, deteriorated alertness, excessive daytime sleepiness and reduced appetite, wherein a combination of an effective amount of cannabinoids selected from the group consisting of tetrahdrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC) and tetrahydrocannabinol (THC), is administered to said mammal, wherein the relative weight ratios of THCV:CBG:CBC:THC are between 1-10:1-10:1-10:1-10.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 30, 2022
    Inventor: Ronald Johannes GLAS
  • USE OF CANNABINOID COMPOUNDS IN ORAL CARE COMPOSITIONS TO INHIBIT THE GROWTH OF P. GINGIVALIS
    Publication number: 20230037975
    Abstract: Methods of inhibiting the growth of Porphyromonas gingivalis (“P. gingivalis”) in the oral cavity using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabinol cannabigerol (“CBG”), cannabigerolic acid (“CBGA”), cannabidiolic acid (“CBDA”), and (+)-cannabidiol (“((+)-CBD”), cannabichromene (“CBC”), cannabinol (“CBN”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabidol-C4 (“CBD-C4”), cannabigerivarin (“CBGV”), cannabigerol butyl (“CBG-C4”), cannabichromenic acid (“CBCA”), cannabicyclolic acid (“CBLA”), and cannabinolic acid (“CBNA”), cannabidol-C2 (“CBD-C2”) and cannabigerolic acid butyl (“CBGA-C4”). The methods can be used to treat or prevent periodontal disease. Compositions and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: July 30, 2022
    Publication date: February 9, 2023
    Inventors: Cynthia W. Bryant, Alison Watta
  • METHOD FOR REDUCTION, SUPPRESSION, OR ELIMINATION OF ANXIETY OR MARIJUANA/CANNABIS EFFECTS AND RELATED MARIJUANA/CANNABIS PRODUCT BY PROCESS
    Publication number: 20190134121
    Abstract: In one aspect, a formulation comprising cannabinoids, paracetamol, methylxanthines, salicylates, terpenes, humulus oil, or amino acids individually or any combination or omission thereof for the reduction, alleviation, elimination, and/or suspension of effects of THC exposure and anxiety. The formulation can be the effective amount of cannabinoid is between 5 mg and 5000 mg. The formulation can be the cannabinoid comprises a Cannabidiol (CBD), a cannabidolic acid (CBDA), a Cannabinol (CBN), a Cannabigerol (CBG), a Cannabichromene (CBC), a Cannabicyclol (CBL), a Cannabivarin (CBV), a Tetrahydrocannabivarin (THCV), a Cannabidivarin (CBDV), a Cannabichromevarin (CBCV), a Cannabigerovarin (CBGV), a Cannabigerol monomethyl ether (CBGM), a Cannabielsoin (CBE), or a cannabicitran (CBT). The formulation can be the effective amount of paracetamol is between 0 mg-1000 mg.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 9, 2019
    Inventors: Steven Bermudez, Aaron Brown
  • PRENYLTRANSFERASE VARIANTS AND METHODS FOR PRODUCTION OF PRENYLATED AROMATIC COMPOUNDS
    Publication number: 20210254030
    Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.
    Type: Application
    Filed: March 8, 2019
    Publication date: August 19, 2021
    Inventors: Michael A. Noble, Kevin G. Hoff, Anna Lechner, Harish Nagarajan
  • PRENYLTRANSFERASE VARIANTS AND METHODS FOR PRODUCTION OF PRENYLATED AROMATIC COMPOUNDS
    Publication number: 20230374473
    Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 23, 2023
    Inventors: Michael A. Noble, Kevin G. Hoff, Anna Lechner, Harish Nagarajan
  • METHOD AND CELL LINE FOR PRODUCTION OF PHYTOCANNABINOIDS AND PHYTOCANNABINOID ANALOGUES IN YEAST
    Publication number: 20200283807
    Abstract: A method and cell line for producing phytocannabinoids and phytocannabinoid analogues in yeast. The method applies, and the cell line includes, a yeast cell transformed with a polyketide synthase CDS and a cytosolic prenyltransferase CDS. The polyketide synthase enzyme catalyzes synthesis of olivetol or methyl-olivetol, and may include Cannabis sativa olivetolic acid synthase or Dictyostelium discoideum polyketide synthase (“DiPKS”). The yeast cell may be modified to include a phosphopantethienyl transferase for increased activity of DiPKS. The yeast cell may be modified to mitigate mitochondrial acetaldehyde catabolism for increasing malonyl-CoA available for synthesizing olivetol or methyl-olivetol. The prenyltransferase enzyme catalyzes synthesis of cannabigerol or a cannabigerol analogue, and may include an ???? cytosolic prenyltransferase enzyme from Streptomyces sp CL190.
    Type: Application
    Filed: February 19, 2018
    Publication date: September 10, 2020
    Inventors: Shoham Mookerjee, Alexander James Campbell, Zachary Douglas Wiltshire, Kevin John Chen
  • Prenyltransferase variants and methods for production of prenylated aromatic compounds
    Patent number: 11685908
    Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 27, 2023
    Assignee: Genomatica, Inc.
    Inventors: Michael A. Noble, Kevin G. Hoff, Anna Lechner, Harish Nagarajan
  • Method and cell line for production of phytocannabinoids and phytocannabinoid analogues in yeast
    Patent number: 11312979
    Abstract: A method and cell line for producing phytocannabinoids and phytocannabinoid analogues in yeast. The method applies, and the cell line includes, a yeast cell transformed with a polyketide synthase CDS and a cytosolic prenyltransferase CDS. The polyketide synthase enzyme catalyzes synthesis of olivetol or methyl-olivetol, and may include Cannabis sativa olivetolic acid synthase or Dictyostelium discoideum polyketide synthase (“DiPKS”). The yeast cell may be modified to include a phosphopantethienyl transferase for increased activity of DiPKS. The yeast cell may be modified to mitigate mitochondrial acetaldehyde catabolism for increasing malonyl-CoA available for synthesizing olivetol or methyl-olivetol. The prenyltransferase enzyme catalyzes synthesis of cannabigerol or a cannabigerol analogue, and may include an ???? cytosolic prenyltransferase enzyme from Streptomyces sp CL190.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: April 26, 2022
    Assignee: Hyasynth Biologicals Inc.
    Inventors: Shoham Mookerjee, Alexander James Campbell, Zachary Douglas Wiltshire, Kevin John Chen
  • Process for the Production of Cannabinoids and Cannabinoid Acids
    Publication number: 20240101503
    Abstract: The present invention relates to a process for the preparation of diverse known and novel cannabinoids 5, which include cannabigerol (CBG, 1), cannabigerolic acid (CBGA, 2), cannabigerovarin (CBGV, 3), cannabigerovarinic acid (CBGVA, 4) and other naturally occurring monocyclic cannabinoids and other analogues from simple inexpensive starting materials using a cascade sequence of allylic rearrangement and aromatization. Novel cannabinoids of series 5 are also claimed as part of the invention. These synthesized cannabinoids, unlike the minor cannabinoids isolated from Cannabis saliva or synthesized from the condensation reactions such as the reactions of substituted resorcinols with monoterpenes, are much easier to obtain at high purity levels. In particular, these cannabinoids, including but not limited to cannabigerol (CBG, 1), cannabigerolic acid (CBGA, 2), cannabigerovarin (CBGV, 3) and cannabigerovarinic acid (CBGVA, 4) are obtained without contamination with impurities with variation in RA and RB (e.g.
    Type: Application
    Filed: October 7, 2020
    Publication date: March 28, 2024
    Inventors: Barry A. Berkowitz, Anthony G. Barrett, Daniel Elliott
  • COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ORTHOLOGOUS ENZYMES
    Publication number: 20220411766
    Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also accept different hydrophobic substrates (e.g., “donor” molecules), compared to wild type controls, to create different minor and novel cannabinoids. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CBGA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 29, 2022
    Inventors: Michael J. MENDEZ, Kyle BOTSCH, Tasha ALTHEIDE, Matthew SAUNDERS
  • Cannabinoid composition and application of the same in preparing medicine for treating neurodegenerative diseases including parkinson's disease and alzheimer's disease
    Patent number: 11497719
    Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 15, 2022
    Inventors: Chendong Zou, Hei Tai, Guijiang Wang, Wan Xiao, Sui Huang
  • TETRAHYDROCANNABINOL EMULSION AND METHOD OF MAKING AND USING
    Publication number: 20210308636
    Abstract: A hemp extract-based emulsion and method for forming includes cannabinoids, including at least tetrahydrocannabinol and cannabigerol, at least one emulsifier, and an aqueous phase. An emulsion of at least the tetrahydrocannabinol is present as droplets suspended in the aqueous phase.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 7, 2021
    Inventor: Brian Brown
  • CANNABINOID-CONTAINING SKIN CARE COMPOSITIONS
    Publication number: 20220287935
    Abstract: Cosmetic or cosmeceutical formulations comprising cannabidiol (CBD), cannabigerol (CBG) and pomegranate seed oil (PSO), products containing same and uses thereof are provided.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 15, 2022
    Applicant: Cannasmetics Ltd.
    Inventors: Ben Yitzhak YELLIN, Nava RAVID
  • METHOD TO TREAT PSORIASIS
    Publication number: 20190060250
    Abstract: A method to treat the skin condition psoriasis is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The topical application is applied at least twice daily for six weeks.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • USE OF PHYTOCANNABINOIDS FOR TREATING MULTIPLE MYELOMA
    Publication number: 20230233583
    Abstract: The present disclosure relates to the use of suitable phytocannabinoids such as cannabidivarin, cannabinol, cannabigerol or cannabichromene or combinations thereof for treatment of multiple myeloma and/or similar conditions, diseases or disorders.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 27, 2023
    Inventors: Massimo Nabissi, Oliviero Marinelli, Cristina Aguzzi, Laura Zeppa, Sazzad Hossain
  • METHODS OF ACCELERATING WOUND HEALING USING CANNABINOID COMPOSITIONS
    Publication number: 20200376156
    Abstract: Provided are methods related to the treatment of epidermal wounds via topical application of a cannabinoid such as, for example, cannabidiol, cannabinol, tetrahydrocannabinol, and cannabigerol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: May 20, 2020
    Publication date: December 3, 2020
    Inventor: Peyton Palaio
  • CANNABIS PLANT WITH INCREASED CANNABIGEROLIC ACID
    Publication number: 20240102034
    Abstract: The present technology generally relates to Cannabis plants having increased cannabigerolic acid (CBGA) and/or cannabigerol (CBG) content. The present technology also generally relates to isolated nucleic acids and isolated amino acids related to same and methods of producing same.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 28, 2024
    Inventor: Daniel Kevin FOWLER
  • STABILITY OF NON-PETROLEUM OILS USING CANNABINOID COMPOUNDS TO PROVIDE ANTIOXIDATIVE BENEFITS
    Publication number: 20230044714
    Abstract: Methods of improving the stability of a non-petroleum oil using cannabinoid compounds are described herein. The cannabinoid compounds can include cannabigerol (“CBG”) and/or cannabigerolic acid (“CBGA”). The cannabinoid compounds can be antioxidants. Compositions and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: July 30, 2022
    Publication date: February 9, 2023
    Inventors: Cynthia W. Bryant, Alison Watta
  • HIGH CANNABIGEROL CANNABIS PLANTS, METHODS OF PRODUCING AND METHODS OF USING THEM
    Publication number: 20200405685
    Abstract: The invention provides compositions and methods for the breeding, production, processing and use of Specialty Cannabis and oannabinoid compositions. The Specialty Cannabis plants, plant parts, plant tissues and plant cells of the present disclosure comprise high levels of CBG in combination with one or more other cannabinoids.
    Type: Application
    Filed: December 7, 2018
    Publication date: December 31, 2020
    Inventors: Mark A. LEWIS, Steven HABA
  • COSMETIC COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240099950
    Abstract: The disclosure provides cosmetic compositions including cannabigerol (CBG), as well as methods of using the same for reducing skin redness, improving skin barrier functionality, brightening the skin of a subject, and enhancing the outward appearance of the skin of a subject (e.g., a male or female human subject).
    Type: Application
    Filed: January 11, 2022
    Publication date: March 28, 2024
    Applicant: Amyris, Inc.
    Inventors: Diva CHAN, Ro OTERI, Ashlee NUNES
Narrow Results

Filter by US Classification